La Jolla’s Long Road To Riquent Approval Takes Another Turn
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
La Jolla Pharmaceutical is modifying an ongoing Phase III trial evaluating its systemic lupus erythematosus candidate Riquent (abetimus) in a manner that will push back the study findings beyond the latest anticipated timeline